1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
Bocian, W.
Kozerski, L.
http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic
C3 H7 N O2
89.093
y
ALANINE
L-peptide linking
C6 H15 N4 O2 1
175.209
y
ARGININE
L-peptide linking
C4 H8 N2 O3
132.118
y
ASPARAGINE
L-peptide linking
C3 H7 N O2 S
121.158
y
CYSTEINE
L-peptide linking
C5 H10 N2 O3
146.144
y
GLUTAMINE
L-peptide linking
C5 H9 N O4
147.129
y
GLUTAMIC ACID
L-peptide linking
C2 H5 N O2
75.067
y
GLYCINE
peptide linking
C6 H10 N3 O2 1
156.162
y
HISTIDINE
L-peptide linking
C6 H13 N O2
131.173
y
ISOLEUCINE
L-peptide linking
C6 H13 N O2
131.173
y
LEUCINE
L-peptide linking
C6 H15 N2 O2 1
147.195
y
LYSINE
L-peptide linking
C9 H11 N O2
165.189
y
PHENYLALANINE
L-peptide linking
C5 H9 N O2
115.130
y
PROLINE
L-peptide linking
C3 H7 N O3
105.093
y
SERINE
L-peptide linking
C4 H9 N O3
119.119
y
THREONINE
L-peptide linking
C9 H11 N O3
181.189
y
TYROSINE
L-peptide linking
C5 H11 N O2
117.146
y
VALINE
L-peptide linking
NE
J.Biomol.Nmr
JBNME9
0800
0925-2738
55
303
309
10.1007/s10858-013-9713-2
23404086
Biosynthetic engineered B28(K)-B29(P) human insulin monomer structure in water and in water/acetonitrile solutions.
2013
2383.698
Insulin
1
syn
polymer
3433.953
Insulin
P28K, K29P
1
syn
polymer
Insulin B chain, Insulin A chain
Insulin B chain, Insulin A chain
no
no
GIVEQCCTSICSLYQLENYCN
GIVEQCCTSICSLYQLENYCN
A
polypeptide(L)
no
no
FVNQHLCGSHLVEALYLVCGERGFFYTKPT
FVNQHLCGSHLVEALYLVCGERGFFYTKPT
B
polypeptide(L)
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
human
sample
INS
9606
Homo sapiens
human
sample
INS
9606
Homo sapiens
repository
Initial release
Database references
1
0
2013-02-27
1
1
2013-05-22
BMRB
Y
RCSB
2012-11-26
REL
REL
REL
structures with the lowest energy
100
20
2D 1H-1H TOCSY
2D 1H-1H NOESY
2D 1H-1H NOESY
2D 1H-13C HSQC
2.5-3.0
mM
2.5-3.0
mM
73
%
27
%
2.5-3.0
mM
2.5-3.0
mM
73
%
27
%
1
2.5
ambient
298
K
torsion angle dynamics, DGSA-distance geometry simulated annealing
1
fewest violations
2.5 - 3.0 mM insulin, residues 90-110, 2.5 - 3.0 mM insulin, residues 25-54, 73 % H2O, 27 % CD3CN, H2O / CD3CN
H2O / CD3CN
2.5 - 3.0 mM insulin, residues 90-110, 2.5 - 3.0 mM insulin, residues 25-54, 73 % D2O-7, 27 % CD3CN-8, D2O / CD3CN
D2O / CD3CN
Case, Darden, Cheatham, III, Simmerling, Wang, Duke, Luo, and Kollman
refinement
AMBER
11
Case, Darden, Cheatham, III, Simmerling, Wang, Duke, Luo, and Kollman
structure solution
AMBER
11
Guntert, Mumenthaler and Wuthrich
refinement
CYANA
2.1
Varian
collection
VNMRJ
2.2 C
Goddard
chemical shift assignment
SPARKY
2.6
500
Varian
Uniform NMR System
Varian Uniform NMR System
GLY
1
n
1
GLY
1
A
ILE
2
n
2
ILE
2
A
VAL
3
n
3
VAL
3
A
GLU
4
n
4
GLU
4
A
GLN
5
n
5
GLN
5
A
CYS
6
n
6
CYS
6
A
CYS
7
n
7
CYS
7
A
THR
8
n
8
THR
8
A
SER
9
n
9
SER
9
A
ILE
10
n
10
ILE
10
A
CYS
11
n
11
CYS
11
A
SER
12
n
12
SER
12
A
LEU
13
n
13
LEU
13
A
TYR
14
n
14
TYR
14
A
GLN
15
n
15
GLN
15
A
LEU
16
n
16
LEU
16
A
GLU
17
n
17
GLU
17
A
ASN
18
n
18
ASN
18
A
TYR
19
n
19
TYR
19
A
CYS
20
n
20
CYS
20
A
ASN
21
n
21
ASN
21
A
PHE
1
n
1
PHE
1
B
VAL
2
n
2
VAL
2
B
ASN
3
n
3
ASN
3
B
GLN
4
n
4
GLN
4
B
HIS
5
n
5
HIS
5
B
LEU
6
n
6
LEU
6
B
CYS
7
n
7
CYS
7
B
GLY
8
n
8
GLY
8
B
SER
9
n
9
SER
9
B
HIS
10
n
10
HIS
10
B
LEU
11
n
11
LEU
11
B
VAL
12
n
12
VAL
12
B
GLU
13
n
13
GLU
13
B
ALA
14
n
14
ALA
14
B
LEU
15
n
15
LEU
15
B
TYR
16
n
16
TYR
16
B
LEU
17
n
17
LEU
17
B
VAL
18
n
18
VAL
18
B
CYS
19
n
19
CYS
19
B
GLY
20
n
20
GLY
20
B
GLU
21
n
21
GLU
21
B
ARG
22
n
22
ARG
22
B
GLY
23
n
23
GLY
23
B
PHE
24
n
24
PHE
24
B
PHE
25
n
25
PHE
25
B
TYR
26
n
26
TYR
26
B
THR
27
n
27
THR
27
B
LYS
28
n
28
LYS
28
B
PRO
29
n
29
PRO
29
B
THR
30
n
30
THR
30
B
author_defined_assembly
2
dimeric
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
1_555
x,y,z
identity operation
0.0000000000
0.0000000000
0.0000000000
1
3.39
0.50
120.30
123.69
B
B
B
NE
CZ
NH1
ARG
ARG
ARG
22
22
22
N
5
3.00
0.50
120.30
123.30
B
B
B
NE
CZ
NH1
ARG
ARG
ARG
22
22
22
N
10
3.21
0.50
120.30
123.51
B
B
B
NE
CZ
NH1
ARG
ARG
ARG
22
22
22
N
12
3.32
0.50
120.30
123.62
B
B
B
NE
CZ
NH1
ARG
ARG
ARG
22
22
22
N
13
-3.99
0.60
121.00
117.01
B
B
B
CB
CG
CD2
TYR
TYR
TYR
26
26
26
N
14
3.28
0.50
120.30
123.58
B
B
B
NE
CZ
NH1
ARG
ARG
ARG
22
22
22
N
1
B
LYS
28
37.71
56.04
2
B
ASN
3
-118.99
70.83
3
B
TYR
26
-84.58
31.41
5
B
GLU
21
-159.99
-10.79
6
B
VAL
2
51.69
-46.89
6
B
PHE
25
-141.62
-32.63
6
B
TYR
26
54.84
134.24
7
B
PHE
24
-139.91
-54.77
8
B
VAL
2
-143.11
-38.66
8
B
GLN
4
65.45
157.84
9
B
ASN
3
-150.75
38.35
9
B
TYR
26
49.58
19.72
10
B
THR
27
57.87
-14.32
12
B
PHE
25
-139.11
-35.82
12
B
TYR
26
47.80
-81.63
13
B
THR
27
56.17
-46.19
13
B
LYS
28
61.82
152.79
14
B
GLU
21
54.08
19.61
14
B
THR
27
53.03
-114.92
15
A
GLN
5
-123.21
-57.16
15
B
PHE
24
-150.67
-43.21
16
B
PHE
25
-140.73
-26.32
16
B
TYR
26
46.83
-97.97
18
B
PHE
24
-136.15
-52.70
18
B
THR
27
58.61
7.74
18
B
LYS
28
32.86
60.63
20
B
PHE
24
-134.83
-78.57
20
B
PHE
25
49.82
71.86
Insulin
fewest violations, model 1
Biosynthetic engineered B28K-B29P human insulin monomer structure in in water/acetonitrile solutions.
1
N
N
2
N
N
A
GLY
1
A
GLY
1
HELX_P
A
CYS
7
A
CYS
7
1
1
7
A
SER
12
A
SER
12
HELX_P
A
GLU
17
A
GLU
17
1
2
6
A
ASN
18
A
ASN
18
HELX_P
A
CYS
20
A
CYS
20
5
3
3
B
GLY
8
B
GLY
8
HELX_P
B
GLY
20
B
GLY
20
1
4
13
disulf
2.034
A
CYS
6
A
SG
CYS
6
1_555
A
CYS
11
A
SG
CYS
11
1_555
disulf
2.037
A
CYS
7
A
SG
CYS
7
1_555
B
CYS
7
B
SG
CYS
7
1_555
disulf
2.030
A
CYS
20
A
SG
CYS
20
1_555
B
CYS
19
B
SG
CYS
19
1_555
HORMONE
Human Insulin, Hormone
INS_HUMAN
UNP
1
90
P01308
GIVEQCCTSICSLYQLENYCN
INS_HUMAN
UNP
2
25
P01308
FVNQHLCGSHLVEALYLVCGERGFFYTPKT
90
110
2M1D
1
21
P01308
A
1
1
21
25
54
2M1D
1
30
P01308
B
2
1
30
2
PRO
ENGINEERED MUTATION
LYS
28
2M1D
B
P01308
UNP
52
28
2
LYS
ENGINEERED MUTATION
PRO
29
2M1D
B
P01308
UNP
53
29